Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data ...
(ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in our Phase 3 ENTRUST trial in SHTG,” stated Rohan Palekar, ...
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable ...
UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...
7d
Hosted on MSNWall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?BIO (ETNB) closed the last trading session at $11.30, gaining 67.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
89bio's pegozafermin, an FGF21 analog, is currently being evaluated in three Phase III trials. Two of these trials are focused on different MASH populations, while the third targets SHTG patients.
89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...
89bio (NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a ...
89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...
89bio, Inc. (NASDAQ:ETNB – Free Report) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of 89bio in a research note issued on Sunday, February 2nd.
89bio (NASDAQ:ETNB – Get Free Report) had its price target boosted by stock analysts at UBS Group from $25.00 to $38.00 in a research note issued on Friday,Benzinga reports.The brokerage ...
89bio, Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results